Wilson Therapeutics’ Nomination Committee appointed
In accordance with the decision of the Annual General Meeting on 17 May 2017, Wilson Therapeutics’ Nomination Committee for the AGM 2018 shall comprise the Chairman of the Board and one representative for each of the three largest shareholders based on ownership of the Company as per the end of September 2017.Accordingly, the following committee members have been appointed: · Andrew Kay, Chairman of the Board · Staffan Lindstrand, representing HealthCap · Sarah Shackelton, representing Abingworth · Thomas Casdagli, representing MVM. The Nomination Committee has appointed